Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CellCyte Genetics has signed a collaborative research agreement with Northwestern University's Feinberg School of Medicine to perform an acute myocardial infarction disease model study in mice using CellCyte's CCG-TH30 product candidate.
Subscribe to our email newsletter
The goal of the study is to evaluate the functional benefit of the CCG-TH30 therapy in a disease model outcome study representative of the AMI (heart attack) indication.
Douglas Losordo, director of the Feinberg Cardiovascular Research Institute, will serve as the principal investigator of the study.
Ronald Berninger, chief scientific officer of CellCyte, said: “This is another important collaboration for our program, as it allows us to evaluate the functional outcome benefit of the CCG-TH30 therapy as compared to standard cell therapies where delivery agents aren’t used.”